Cereno Scientific (CRNO) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Three differentiated programs advanced: CS1 in Phase IIb for PAH, CS014 preparing for Phase IIb in PH-ILD, and preclinical CS585 targeting rare thrombotic diseases.
Positive CS014 PK bridging results supported a proposed direct path toward Phase IIb, subject to FDA review; EPIMODE site activation and patient recruitment readiness continued.
Financial highlights
Q3 2026 operating loss was SEK 17.9m versus SEK 13.5m in Q3 2025; loss after financial items was SEK 27.4m versus SEK 21.3m.
9M 2026 operating loss was SEK 58.8m versus SEK 47.4m; loss after financial items was SEK 86.5m versus SEK 73.0m.
Cash and cash equivalents were SEK 40.2m at September 30, 2026, versus SEK 74.2m a year earlier; equity ratio was 47.6% versus 49.5%.
Outlook and guidance
EPIMODE targets up to 15 activated sites by end-2026 and more than half of planned sites by end-Q1 2027; recruitment completion is targeted during 2027 and topline results in Q4 2028, subject to recruitment timelines.
CS014 IND submission is planned for Q4 2026 and Phase IIb initiation for Q3 2027, subject to regulatory approval and completion of preparations.
Additional capital will be needed to execute development plans at the intended pace; financing and partnership options remain under evaluation.
Latest events from Cereno Scientific
- Advancing first-in-class HDAC inhibitors for rare cardiopulmonary diseases with strong clinical and market momentum.CRNO
Company presentation - Clinical execution milestones achieved and financial position strengthened for continued pipeline advancement.CRNO
Q2 2026 - CS1 advances to Phase IIb in PAH as Q1 loss reaches SEK -21.9M; cash at SEK 70.9M.CRNO
Q1 2026 - Advanced to global Phase IIb for PAH, secured major financing, and sharpened pipeline focus.CRNO
Q4 2025 - CS1 advances to global phase IIb for PAH, targeting disease modification and $3B peak sales.CRNO
CMD 2026 - Two Phase 2 trials in rare diseases to launch next year, backed by FDA Fast Track and global partners.CRNO
GoCo Investor Days - Positive phase II-A results in PAH, FDA engagement, and funding secured through 2026.CRNO
ABGSC Investor Days - CS1 met safety and efficacy signals in PAH, supporting advancement to pivotal trials.CRNO
Study Result - Rare disease pipeline advances with strong clinical data, new indications, and strategic partnerships.CRNO
CMD 2024